Search results for "Diphtheria"

showing 10 items of 70 documents

Novel Microglia Depletion Systems: A Genetic Approach Utilizing Conditional Diphtheria Toxin Receptor Expression and a Pharmacological Model Based on…

2019

Microglia are the main population of macrophage residing in the central nervous system (CNS). Depletion experiments gave important insights into the physiology and function of microglia in healthy and diseased CNS. Ablation of microglia can be achieved by application of pharmacological or genetic tools. Here, we describe two approaches to ablate microglia: an efficient genetic model that utilizes DTRMG mouse line that has diphtheria toxin receptor (DTR) expression regulated by the promoter activity of the fractalkine receptor (CX3CR1) gene, and a pharmacological model that utilizes the blocking of macrophage colony-stimulating factor 1 receptor (CSF-1R) with a blocking antibody. Both the ad…

0301 basic medicineDiphtheria toxinMacrophage Colony-Stimulating Factor 1 Receptoreducation.field_of_studyMicrogliaPopulationBiologyCell biology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureGenetic modelBlocking antibodyCX3CR1medicineeducationReceptor030217 neurology & neurosurgery
researchProduct

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner

2007

Gammaherpesviruses are important pathogens whose lifelong survival in the host depends critically on their capacity to establish and reactivate from latency, processes regulated by both viral genes and the host immune response. Previous work has demonstrated that gamma interferon (IFN-gamma) is a key regulator of chronic infection with murine gammaherpesvirus 68 (gammaHV68), a virus that establishes latent infection in B lymphocytes, macrophages, and dendritic cells. In mice deficient in IFN-gamma or the IFN-gamma receptor, gammaHV68 gene expression is altered during chronic infection, and peritoneal cells explanted from these mice reactivate more efficiently ex vivo than cells derived from…

1109 Insect Sciencemedicine.medical_treatmentImmunologyCellSpleen610 Medicine & healthBiology10263 Institute of Experimental ImmunologyMicrobiologyInterferon-gammaGammaherpesvirinaeImmune systemVirologyVirus latencymedicineAnimalsHumansInterferon gammaDiphtheria toxinB-Lymphocytes2403 ImmunologyMacrophages2404 MicrobiologyHerpesviridae Infectionsmedicine.diseaseVirus LatencyCell biologyChronic infectionCytokinemedicine.anatomical_structureInsect ScienceImmunology2406 VirologyPathogenesis and Immunity570 Life sciences; biologyVirus Activationmedicine.drug
researchProduct

Pertussis vaccines--1993.

1993

AdolescentWhooping CoughJapanmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionChildWhooping coughDiphtheria-Tetanus-Pertussis Vaccinemedia_commonPertussis Vaccinebusiness.industryInfant NewbornInfantDiphtheria-Tetanus-Pertussis Vaccinemedicine.diseaseInfant newbornVaccinationEuropeChild PreschoolPediatrics Perinatology and Child HealthImmunologyPertussis vaccinebusinessTos ferinamedicine.drugForecastingEuropean journal of pediatrics
researchProduct

The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg.

1998

Nonresponsiveness to HBsAg vaccination is observed in 5-10% of vaccine recipients and is possibly caused by a defect in the T helper cell compartment. The immune response to HBsAg is influenced by genes of the major histocompatibility complex. We have investigated MHC class I and class II antigens in 53 adult responders and 73 nonresponders. Results obtained in this first study were tested in a second study with 56 responders and 62 nonresponders from an infant vaccination trial. In addition, the peripheral Vbeta-chain T-cell receptor repertoire was investigated using monoclonal antibodies and flow-cytometry in 26 adult responders and 38 nonresponders. As previously reported, nonresponsiven…

AdultHBsAgT cellReceptors Antigen T-Cell alpha-betaImmunologyGenes MHC Class IIMajor histocompatibility complexCohort StudiesImmune systemGene FrequencyMHC class ImedicineImmunology and AllergyHumansHepatitis B VaccinesAllelesDiphtheria-Tetanus-Pertussis VaccineHepatitis B Surface AntigensbiologyT-cell receptorInfantGeneral MedicineT helper cellHLA-DR AntigensVirologyVaccinationmedicine.anatomical_structureImmunologybiology.proteinImmunizationHLA-DRB1 ChainsHuman immunology
researchProduct

Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults

2000

Abstract To assess the reactogenicity and immunogenicity of the Biken acellular pertussis vaccine (Pa) following administration of a single vaccine dose to young adults with or without a history of prior pertussis immunization, 104 healthy, male and female adults without primary pertussis immunization were enrolled in Mainz (former West Germany; “not previously pertussis vaccinated”, N-PPV-group); in parallel, 103 adults with a history of having received ≥four doses of a combined diphtheria-, tetanus-toxoid, whole-cell pertussis vaccine (DTwP) were enrolled in Magdeburg (former East Germany; “previously pertussis-vaccinated”, PPV-group). Large areas of redness (>20 mm) were seen in 2.9%/1.0…

AdultMaleDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisVaccines AcellularHumansMedicineVirulence Factors BordetellaYoung adultAdhesins BacterialWhooping coughPertussis VaccineReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthToxoidAntibody titerToxoidsmedicine.diseaseAntibodies BacterialHemagglutininsInfectious DiseasesImmunologyMolecular MedicinePertussis vaccineFemaleSafetybusinessmedicine.drugVaccine
researchProduct

Experts’ Opinion for Improving Pertussis Vaccination Rates in Adolescents and Adults: A Call to Action

2022

This article highlights the importance of diphtheria-tetanus-acellular pertussis (with reduced antigen content, dTap) vaccination in preventing pertussis, a respiratory infection that is still widespread and easily transmitted. In particular, it highlights the need to receive a booster vaccination throughout life to maintain high antibody levels, which decrease through time. This document collects the opinions that emerged from the comparison between major Italian experts in the field of vaccination. This working group was created to promote a “call to action”, aimed at raising awareness among all institutions, public health authorities, and health workers involved in the vaccination proces…

AdultTetanuspertussis vaccineAdolescentWhooping CoughHealth Toxicology and MutagenesisVaccinationpertussis vaccine in pregnancy.Public Health Environmental and Occupational Healthpertussis booster for adultDiphtheriapertussis immunity durationDiphtheria-Tetanus-acellular Pertussis VaccinesAntibodies Bacterialpertussis immunizationdTap vaccinePregnancypertussiHumansFemaleDiphtheria-Tetanus-Pertussis VaccineInternational Journal of Environmental Research and Public Health
researchProduct

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

2003

The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrixtrade mark) has been shown to induce a strong booster response to all the vaccine components in 4-6 year olds. However, anti-diphtheria antibody levels were observed to be lower when compared to the "full strength" paediatric DTPa vaccine. To assess the impact of this difference on long-term protection, a mathematical model was developed to predict diphtheria antibody decay over time. The model was based on a linear decrease in log-transformed antibody concentrations after the first year post-vaccination. When applied to data collected 3.5 years after vaccination of 4-6 year olds with either DTPa or dTpa, …

AdultTime Factorsanimal diseasesImmunization SecondaryModels Biologicalcomplex mixturesCohort StudiesAntigenmedicineHumansChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleRandomized Controlled Trials as TopicBooster (rocketry)General VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaVaccinationPublic Health Environmental and Occupational HealthDiphtheriarespiratory systemmedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationChild PreschoolImmunologycardiovascular systembiology.proteinMolecular MedicineAntibodybusinessDiphtheria antibodycirculatory and respiratory physiologyVaccine
researchProduct

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine.

1994

The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-lin…

Bordetella pertussisbiologybusiness.industryDiphtheriaFilamentous haemagglutinin adhesinbiology.organism_classificationmedicine.diseasePertussis toxincomplex mixturesVirologyVaccinationVaccino pertosse; immunogenicità; tossina; vaccinazione; bambiniPediatrics Perinatology and Child HealthImmunologymedicinePertussis vaccinePertactinBORDETELLA-PERTUSSISbusinessWhooping coughmedicine.drug
researchProduct

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

2011

Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lower antibody levels, or enhancement [higher antibody levels]) when coadministered with other vaccines. Immune enhancement occurs when two TT conjugates are coadministered. CRM(197) conjugate vaccines induce immune bystander interference when given with diphtheria-tetanus-acellular pertussis vaccines, which reduces responses to coadministered Haemophilus influenzae type b vaccine conjugated to TT. These bystander effects are greater as the amount of CRM(197) administered increases. When large am…

Diphtheria ToxoidImmunologyMeningococcal vaccinecomplex mixturesImmune systemAdjuvants ImmunologicBacterial ProteinsDrug DiscoverymedicineBystander effectTetanus ToxoidHumansDrug InteractionsImmunization SchedulePharmacologyDiphtheria toxinDrug CarriersVaccines ConjugateTetanusbusiness.industryToxoidmedicine.diseaseVirologyVaccinationPneumococcal vaccineImmunologyBacterial VaccinesMolecular MedicinebusinessExpert review of vaccines
researchProduct